Rock Springs Capital — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesHercules Capital, Inc.+8 more
Honor Technology develops technology platforms and operates brands that provide goods and services for aging adults, aiming to support independent living.
Digital HealthHealthtechLongevitySaaSSan Francisco, US
Cameron Ring(Founder)inMonica Doss(Co-Founder)Monica Lo(Founder)inSandy Jen(Founder)inSeth Sternberg(Founder)inLori Hogan.(Founder)
Co-investorsAndreessen HorowitzBaillie Gifford8VCAlumni VenturesBAM VenturesEnsemble Labs+7 more
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsEmpire AngelsGaingelsSand Hill AngelsVoyager CapitalAlly Bridge GroupAmed Ventures+6 more
Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.
Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US
Ian Laffey(Chief Executive Officer)inSacha Lévy(Chief Technology Officer)inCarl Schoeller(Founder)Yasmin Acevedo(Recruiter)Luca Lery Moffat(COO)
Co-investorsY CombinatorFirst Round CapitalPioneerAntlerEndor CapitalForesite Capital+7 more
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalNextech InvestNexTech VenturesOmega FundsOrbiMed+2 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersWellington Management+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




















__Twitter.png)

















